Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering
Rhea-AI Summary
Propanc Biopharma (NASDAQ:PPCB), a biopharmaceutical company focused on novel cancer treatments, has announced its uplisting to the Nasdaq Capital Market and pricing of a $4 million public offering. The company is offering 1,000,000 shares at $4.00 per share, with an additional 45-day option for underwriters to purchase up to 150,000 shares.
Trading on Nasdaq is set to begin on August 15, 2025, transitioning from the OTC Markets Pink Tier. The offering, expected to close on August 18, 2025, will be managed by D. Boral Capital LLC and Craft Capital Management LLC. Proceeds will be used for working capital and general business purposes.
Positive
- Uplisting to Nasdaq Capital Market enhances company visibility and potential investor access
- Successfully raised $4 million through public offering to support operations
- Maintains same ticker symbol (PPCB) for continuity
Negative
- Potential dilution for existing shareholders from 1 million new shares
- Additional dilution possible if 150,000-share underwriter option is exercised
News Market Reaction
On the day this news was published, PPCB declined 72.40%, reflecting a significant negative market reaction. Argus tracked a trough of -35.9% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $134M from the company's valuation, bringing the market cap to $51M at that time. Trading volume was exceptionally heavy at 81.1x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Propanc common stock expected to begin trading on Nasdaq under the symbol PPCB
MELBOURNE, Australia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced the pricing of an underwritten public offering of 1,000,000 shares of its common stock, par value
In connection with the offering, the Company has also granted the underwriter a 45-day option to purchase up to 150,000 additional shares of common stock. The offering is expected to close on August 18, 2025, subject to customary closing conditions. On August 14, 2025, the Company received approval to list its common stock on the Nasdaq Capital Market stock exchange (“Nasdaq”). Trading on Nasdaq is expected to commence on August 15, 2025, subject to continued compliance with the exchange rules.
The Company’s shares of common stock were previously quoted on the OTC Markets, Pink Tier and ceased to be quoted at the close of business on August 14, 2025. Stockholders are not required to take any action as a result of the uplisting, and the Company’s ticker symbol “PPCB” will remain unchanged.
D. Boral Capital LLC and Craft Capital Management LLC are acting as book running managers for the offering.
A registration statement on Form S-1 relating to these securities was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on August 13, 2025. These securities may not be sold, nor may offers to buy these securities be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The proposed offering will be made only by means of a prospectus. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the SEC’s website at http://www.sec.gov.
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian, and colorectal cancers. For more information, please visit www.propanc.com.
The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com
Investor Contact:
irteam@propanc.com
FAQ
When will Propanc Biopharma (PPCB) begin trading on Nasdaq?
How much is Propanc Biopharma's public offering worth and at what price?
What will Propanc Biopharma use the proceeds from the public offering for?
Who are the underwriters for Propanc Biopharma's public offering?
What is the additional share purchase option granted to the underwriter?
